Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection

NAActive, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2026

Conditions
Aortic Dissection Type B
Interventions
DEVICE

Relay Pro Stent-Graft

Endovascular treatment of an aortic dissection

Trial Locations (21)

14203

Buffalo General Medical Center, Buffalo

19096

Lankenau Medical Center, Wynnewood

19104

University of Pennsylvania Medical Center / Penn Presbyterian, Philadelphia

20010

Medstar Washington Hospital Center, Washington D.C.

21201

University of Maryland Medical Center (UMB), Baltimore

22042

Sentara Heart Hospital, Norfolk

24014

Carilion Roanoke Memorial Hospital, Roanoke

30322

Emory University, Atlanta

44106

University Hospitals, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

46260

St. Vincent Heart Center, Indianapolis

52242

University of Iowa Hospital and Clinic, Iowa City

53226

Medical College of WI, Vascular Surgery, Milwaukee

60611

Northwestern Memorial Hospital, Chicago

80045

University of Colorado Denver, Aurora

90033

USC Department of Surgery, Los Angeles

97213

Providence Heart Institute, Portland

98105

University of Washington, Seattle

06102

Hartford Hospital, Hartford

06520

Yale School of Medicine, New Haven

48109-5868

University of Michigan Health System, Ann Arbor

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bolton Medical

INDUSTRY

NCT03033043 - Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection | Biotech Hunter | Biotech Hunter